Boster Immunoleader

antibody

Anti-LOX 1 Antibody

PA1832

100 ug/vial

200 USD

polyclonal

rabbit

Anti-LOX 1 Antibody

PA1832

Polyclonal

Rabbit IgG polyclonal antibody for Oxidized low-density lipoprotein receptor 1(OLR1) detection. Tested with WB in Human.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human

Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the N-terminus of human LOX 1(1-16aa MTFDDLKIQTVKDQPD).

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

OLR1(oxidized low density lipoprotein(lectin-like) receptor 1) also called CLEC8A, LOX-1, SCARE1, is a receptor protein which belongs to the C-type lectin superfamily. The OLR1 gene encodes a cell-surface endocytosis receptor for oxidized low density lipoprotein(OxLDL). The OLR1 gene is mapped on 12p13.2. Incubation of the cells with LDL had no effect on LOX1 expression, but incubation with OxLDL resulted in a dose-dependent increase in LOX1 mRNA and protein expression; however, very high concentrations of OxLDL caused a decrease in OxLDL expression, perhaps indicating toxic effects on endothelial cells. LOX1 was also expressed in macrophages, but not in vascular smooth muscle cells. The findings suggested a role for LOX1 in the pathophysiology of atherosclerotic cardiovascular disease. LOX1 expression was detected in all choroidal neovascular membranes, regardless of structure, whereas there was no evidence of LOX1 within the posterior segments of normal eyes. LOX1 plays an active role in the pathogenesis of choroidal neovascularization, especially in ARMD.

1. Aoyama, T., Sawamura, T., Furutani, Y., Matsuoka, R., Yoshida, M. C., Fujiwara, H., Masaki, T. Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene. Biochem. J. 339: 177-184, 1999. 2. Delneste, Y., Magistrelli, G., Gauchat, J.-F., Haeuw, J.-F., Aubry, J.-P., Nakamura, K., Kawakami-Honda, N., Goetsch, L., Sawamura, T., Bonnefoy, J.-Y., Jeannin, P. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17: 353-362, 2002. 3. Luedecking-Zimmer, E., DeKosky, S. T., Chen, Q., Barmada, M. M., Kamboh, M. I. Investigation of oxidized LDL-receptor 1 (OLR1) as the candidate gene for Alzheimer's disease on chromosome 12. Hum. Genet. 111: 443-451, 2002.

OLR1

Oxidized low-density lipoprotein receptor 1(Ox-LDL receptor 1)

oxidized low density lipoprotein(lectin-like) receptor 1

C-type lectin domain family 8 member A antibody CLEC8A antibody hLOX 1 antibody hLOX-1 antibody Lectin like oxidized LDL receptor 1 antibody Lectin like oxLDL receptor 1 antibody Lectin type oxidized LDL receptor 1 antibody Lectin-like oxidized LDL receptor 1 antibody Lectin-like oxLDL receptor 1 antibody Lectin-type oxidized LDL receptor 1 antibody LOX-1 antibody LOXIN antibody Olr1 antibody OLR1_HUMAN antibody Ox LDL receptor 1 antibody Ox-LDL receptor 1 antibody Oxidised low density lipoprotein(lectin like) receptor 1 antibody Oxidized low density lipoprotein receptor 1 antibody Oxidized low density lipoprotein receptor 1 soluble form antibody Oxidized low-density lipoprotein receptor 1 antibody SCARE1 antibody Scavenger receptor class E, member 1 antibody SLOX1 antibody soluble form antibody SR-EI antibody

P78380